These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39025724)

  • 1. Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology.
    Ma SB; Lin W; Campbell J; Clerici K; White D; Yeung D; Gorniak M; Fleming S; Fong CY; Agarwal R
    Pathology; 2024 Dec; 56(7):982-992. PubMed ID: 39025724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
    Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
    Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
    Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
    Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
    Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.
    Huang YJ; Chen SH; Liu HC; Jaing TH; Yeh TC; Kuo MC; Lin TL; Chen CC; Wang SC; Chang TK; Hsiao CC; Liang DC; Shih LY
    Pathology; 2024 Aug; 56(5):681-687. PubMed ID: 38719770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
    Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC
    Pathology; 2024 Oct; 56(6):882-888. PubMed ID: 39025727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Yan N; Wang ZL; Wang XJ; Gale RP; Zhou YL; Zhao MY; Wu LX; Liao MY; Yang J; Wang CY; Zhu JH; Jiang H; Jiang Q; Liu YR; Chang YJ; Xu LP; Zhang XH; Ma TH; Huang XJ; Ruan GR
    Cancer Lett; 2024 Aug; 598():217104. PubMed ID: 38969163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
    Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
    Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
    Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
    Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
    Muffly L; Liang EC; Dolan JG; Pulsipher MA
    Blood; 2024 Jul; 144(3):253-261. PubMed ID: 38728375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
    Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
    Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
    Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
    Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing.
    Ahn WK; Yu K; Kim H; Lee ST; Choi JR; Han JW; Lyu CJ; Hahn S; Shin S
    Cancer Cell Int; 2024 Jun; 24(1):218. PubMed ID: 38918782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
    Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
    J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.